Skip to main content
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
Dietary Interventions in PsA
EULAR 2026 RA Topic Panel https://t.co/lLSL6FW9sg

Dr. John Cush RheumNow

1 month 2 weeks ago
EULAR 2026 RA Topic Panel https://t.co/lLSL6FW9sg
Immune Dimming or Immune Reset in RA: How Far Should We Go?

CD19 CAR T-cell therapy has moved from oncology to autoimm

Dr. John Cush RheumNow

1 month 2 weeks ago
Immune Dimming or Immune Reset in RA: How Far Should We Go? CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j
New: Classification Criteria and Recommendations in SpA

ASAS and SPARTAN have updated their key classification criteri

Dr. John Cush RheumNow

1 month 2 weeks ago
New: Classification Criteria and Recommendations in SpA ASAS and SPARTAN have updated their key classification criteria for axSpA. EULAR has also recently revised its recommendations on the role of imaging in the diagnosis and clinical management of SpA. https://t.co/YOWfwTkbqp
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this spectrum, from patient-facing education to diagnostic reasoning.
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
CAR-T Topic Panel: EULAR 2026
Improving Referrals for Inflammatory Arthritis

Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EU

Dr. John Cush RheumNow

1 month 2 weeks ago
Improving Referrals for Inflammatory Arthritis Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj
Gout and ULT Withdrawal -- The GO TEST FINALE Trial

Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2

Dr. John Cush RheumNow

1 month 2 weeks ago
Gout and ULT Withdrawal -- The GO TEST FINALE Trial Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London https://t.co/d8U1168SRn https://t.co/hP0EUrciTu
Day 3 Recap: EULAR 2026

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstract

Dr. John Cush RheumNow

1 month 2 weeks ago
Day 3 Recap: EULAR 2026 Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288 https://t.co/TSnVVOpF75 https://t.co/EFD0WKRpF4
Exploring Idiopathic Myopathies

#EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune

Dr. John Cush RheumNow

1 month 2 weeks ago
Exploring Idiopathic Myopathies #EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z
PsA Topic Panel: EULAR 2026
×